Share This Page
Drug Sales Trends for INDERAL LA
✉ Email this page to a colleague
Annual Sales Revenues and Units Sold for INDERAL LA
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| INDERAL LA | ⤷ Start Trial | ⤷ Start Trial | 2022 |
| INDERAL LA | ⤷ Start Trial | ⤷ Start Trial | 2021 |
| INDERAL LA | ⤷ Start Trial | ⤷ Start Trial | 2020 |
| INDERAL LA | ⤷ Start Trial | ⤷ Start Trial | 2019 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
Inderal LA Market Analysis and Sales Projections
Inderal LA is a mature extended-release propranolol hydrochloride product with limited commercial growth potential. Its U.S. market is largely genericized, and no meaningful patent-based exclusivity remains. Brand sales depend on physician familiarity, payer coverage, supply reliability, and continued use among patients who remain stable on the branded product.
A reasonable base-case estimate places U.S. Inderal LA brand revenue at approximately $8 million to $12 million annually, with flat to low-single-digit annual growth through 2030. The broader U.S. propranolol market is materially larger because it includes immediate-release tablets, oral solutions, injections, and generic extended-release capsules.
What is Inderal LA and how is it used?
Inderal LA contains propranolol hydrochloride in an extended-release capsule formulation. Propranolol is a nonselective beta-adrenergic blocker used across cardiovascular, neurologic, and other indications.
Typical uses include:
- Hypertension
- Angina pectoris
- Atrial fibrillation and other tachyarrhythmias
- Migraine prophylaxis
- Essential tremor
- Hypertrophic subaortic stenosis
- Pheochromocytoma as part of combination management
- Certain off-label uses, including performance anxiety and portal hypertension
The extended-release formulation is generally dosed once daily. Immediate-release propranolol remains widely prescribed because it allows flexible titration and is used for indications requiring short-duration or symptom-triggered treatment.
Product and regulatory profile
| Attribute | Inderal LA |
|---|---|
| Active ingredient | Propranolol hydrochloride |
| Dosage form | Extended-release oral capsule |
| Route | Oral |
| Drug class | Nonselective beta blocker |
| U.S. regulatory pathway | Abbreviated New Drug Application and legacy NDA market |
| Original innovator | Wyeth, later associated with Pfizer’s legacy portfolio |
| Current commercial market | Genericized U.S. market |
| Primary competitors | Generic propranolol ER capsules, immediate-release propranolol |
| FDA biologic status | Not applicable |
| Biosimilar exposure | None |
Inderal LA is a small-molecule drug, not a biologic. Biosimilar competition does not apply. The commercial risk is generic substitution rather than biosimilar erosion.
What is the U.S. market size for propranolol and Inderal LA?
The U.S. propranolol market should be divided into two segments:
- The total propranolol market, including immediate-release and extended-release products.
- The branded Inderal LA segment, which is a much smaller portion of the market.
Public FDA and prescription databases do not provide a single authoritative, current figure for net Inderal LA sales. Brand-level revenue is also affected by rebates, institutional purchasing, specialty pharmacy distribution, and private-label generic supply. The following market ranges are therefore modeled estimates rather than reported company revenue.
Estimated U.S. annual market
| Segment | Estimated annual U.S. value | Market position |
|---|---|---|
| All propranolol products | $150 million-$300 million | Mature, generic-dominated |
| Propranolol extended-release products | $25 million-$60 million | Smaller, formulation-specific segment |
| Inderal LA brand | $8 million-$12 million | Niche branded segment |
| Generic propranolol ER | $15 million-$45 million | Primary price competitor |
| Propranolol immediate-release products | $100 million-$240 million | Larger prescription base |
These ranges reflect the mature status of propranolol, the availability of multiple generic dosage forms, and the relatively limited clinical differentiation between brand and generic extended-release capsules.
The branded product retains value in prescriptions that are not automatically substituted, in patients who remain stable on the brand, and in channels where product continuity is prioritized. That value is constrained by generic substitution laws and payer preference.
What are the Inderal LA sales projections through 2030?
The base-case forecast assumes continued availability, stable prescribing, no material label expansion, and gradual price pressure. It excludes a major supply disruption or acquisition-driven relaunch.
Base-case Inderal LA U.S. revenue projection
| Year | Estimated net sales | Year-over-year change | Key assumption |
|---|---|---|---|
| 2024A | $9.5 million | - | Estimated baseline |
| 2025E | $9.3 million | -2.1% | Stable demand, modest payer pressure |
| 2026E | $9.2 million | -1.1% | Continued generic substitution |
| 2027E | $9.2 million | 0.0% | Mature brand retention |
| 2028E | $9.3 million | 1.1% | Price and channel stabilization |
| 2029E | $9.4 million | 1.1% | Stable prescription base |
| 2030E | $9.5 million | 1.1% | Flat-volume, low-price-growth case |
The base case implies a compound annual growth rate of approximately 0% from 2024 through 2030. Inderal LA is more likely to produce stable cash flow than significant unit growth.
Scenario analysis
| Scenario | 2025 sales | 2030 sales | 2024-2030 CAGR | Main drivers |
|---|---|---|---|---|
| Downside | $6.5 million | $4.0 million | -11% | Formulary exclusion, generic price cuts, supply weakness |
| Base case | $9.3 million | $9.5 million | 0% | Stable brand retention |
| Upside | $12.5 million | $16.0 million | 9% | Supply disruption among generics, stronger contracting, price realization |
The upside case requires conditions that are not currently inherent in the product. A meaningful increase in sales would probably depend on generic shortages, a distribution agreement, a targeted institutional strategy, or a new indication. Organic prescription growth alone is unlikely to support sustained high-single-digit expansion.
How does Inderal LA compare with generic propranolol?
Generic propranolol is the main competitive threat. The generic market includes extended-release capsules that are therapeutically substitutable in many payer and pharmacy settings.
| Factor | Inderal LA | Generic propranolol ER |
|---|---|---|
| Price | Higher | Lower |
| Prescriber familiarity | High among legacy users | High |
| Automatic substitution | Usually subject to payer and state rules | Preferred |
| Formulation differentiation | Limited | Limited |
| Clinical evidence | Established | Relies on bioequivalence |
| Payer position | Generally unfavorable | Favorable |
| Supply risk | Product-specific | Spread across manufacturers |
| Growth potential | Low | Volume can grow through substitution |
Inderal LA may preserve demand among patients who have used it for years, physicians who specify the product, and pharmacies that maintain continuity for stable patients. Generic substitution remains the dominant long-term pressure.
Immediate-release propranolol is also a competitor. It is often less expensive and gives prescribers greater flexibility. It is not a perfect substitute for a once-daily extended-release product, but it limits the addressable market for Inderal LA.
What patents protect Inderal LA?
Inderal LA’s principal commercial protection was historically based on formulation and regulatory exclusivity rather than an enduring patent estate. The core propranolol compound is long off patent, and the extended-release technology does not provide meaningful current market exclusivity.
Patent position
| Protection category | Current assessment |
|---|---|
| Propranolol compound patent | Expired |
| Original extended-release formulation protection | Expired or commercially ineffective |
| Active Orange Book patent barrier | No material current barrier identified |
| Regulatory exclusivity | Expired |
| Method-of-use protection | No commercially meaningful exclusivity identified |
| Manufacturing protection | Possible process know-how, but not a practical market block |
| Biosimilar protection | Not relevant |
The product’s remaining commercial value is therefore based on brand equity, customer retention, distribution, and product availability rather than patent exclusion.
What formulations are protected by Inderal LA?
The relevant formulation concept is a once-daily extended-release propranolol capsule. The formulation historically distinguished Inderal LA from immediate-release propranolol, but generic extended-release products have substantially reduced the commercial value of that distinction.
Any residual formulation know-how may include:
- Drug-release control
- Capsule fill composition
- Particle-size management
- Dissolution performance
- Stability and manufacturing controls
These elements can create technical execution requirements but do not necessarily create enforceable market exclusivity. A generic manufacturer may use a different formulation that meets FDA bioequivalence and quality requirements.
What is the Orange Book status of Inderal LA?
Inderal LA is associated with a legacy prescription drug approval and has no known current patent-based barrier that would prevent abbreviated new drug application competition.
The commercial implications are:
- Generic manufacturers do not need to wait for a future patent expiration to enter.
- Paragraph IV litigation is not the primary current risk.
- ANDA approvals and generic manufacturing capacity determine competitive intensity.
- Any new patent listing would need to satisfy FDA listing requirements and withstand invalidity and non-infringement challenges.
The absence of a current patent barrier reduces legal uncertainty but increases price and share pressure. The relevant issue is not whether generic entry can occur, but how many approved manufacturers remain active and how aggressively they compete.
Which companies compete with Inderal LA?
Competition comes from generic manufacturers rather than another major branded innovator.
Potential competitors in the U.S. propranolol market include manufacturers of generic propranolol ER and immediate-release products such as:
- Teva Pharmaceuticals
- Actavis or Amneal-related generic operations
- Par Pharmaceutical
- Sandoz
- Zydus Pharmaceuticals
- Rising Pharmaceuticals
- Other FDA-approved ANDA holders and contract manufacturers
The active supplier set can change because generic companies periodically discontinue low-margin products, transfer ANDAs, or reduce manufacturing capacity. That creates a supply-based opportunity for a branded product but also increases dependence on reliable manufacturing.
Are there Paragraph IV challenges or patent litigation involving Inderal LA?
No current high-value Paragraph IV campaign is central to Inderal LA’s commercial outlook. The product is a mature, genericized medicine, and its original exclusivity period has ended.
Litigation assessment
| Issue | Current commercial impact |
|---|---|
| Paragraph IV challenge | Low |
| ANDA patent litigation | Low |
| Brand-generic settlement risk | Low |
| Product liability | Conventional pharmaceutical risk |
| Manufacturing litigation | Possible but not central |
| Trademark disputes | Possible, limited economic effect |
| Patent reissue strategy | Unlikely to change market structure |
A future litigation event could arise from a new formulation, manufacturing patent, or regulatory dispute, but that would not be part of the base-case forecast. The existing market does not depend on a pending patent settlement.
What is the FDA regulatory status of Inderal LA?
Inderal LA is an FDA-approved prescription product. Propranolol has a long clinical history and is widely recognized as an established active pharmaceutical ingredient.
The regulatory profile is favorable in terms of clinical familiarity but offers limited commercial differentiation. The primary regulatory requirements concern:
- Continued compliance with current good manufacturing practices
- Stability and dissolution specifications
- Labeling compliance
- Pharmacovigilance
- Manufacturing-site inspection status
- Bioequivalence for competing generic products
- Supply-chain continuity
A new branded lifecycle strategy would require regulatory investment. Possible approaches could include a new dosage strength, an alternative delivery system, pediatric positioning, or a combination product. None would automatically create a commercially attractive opportunity.
What generic entry risks exist for Inderal LA?
Generic entry is already established. The relevant risk is continued generic erosion rather than a one-time launch event.
Principal risks
Payer-driven substitution. Pharmacy benefit managers and health plans generally favor lower-cost generic propranolol.
Brand-to-generic conversion. Existing Inderal LA patients can be switched when prescriptions are renewed or when pharmacies apply substitution rules.
Price compression. Multiple generic suppliers can reduce average selling prices, limiting the branded product’s ability to maintain a premium.
Formulary exclusion. The brand may be excluded from preferred tiers or reimbursed only after generic failure.
Prescriber substitution. Physicians may select immediate-release propranolol where once-daily dosing is not essential.
Supply disruption. Shortages among generic manufacturers can temporarily improve brand demand, but this effect is unpredictable and generally reversible.
The most likely long-term outcome is low-single-digit annual erosion in brand units offset partly by price increases and channel management.
How strong is the Inderal LA commercial position?
Inderal LA has moderate residual brand strength but weak structural protection.
| Strength factor | Assessment |
|---|---|
| Clinical familiarity | Strong |
| Patient loyalty | Moderate |
| Patent protection | Weak or absent |
| Payer access | Weak to moderate |
| Generic differentiation | Weak |
| Manufacturing complexity | Moderate |
| Supply-chain value | Moderate |
| Pricing power | Low |
| Lifecycle expansion potential | Low |
| Revenue durability | Moderate at low scale |
The product can remain commercially viable because mature brands often retain a stable prescription base. Its value is more consistent with a cash-generating legacy asset than with a growth pharmaceutical asset.
What licensing deals could affect Inderal LA?
A licensing or distribution agreement could change the revenue profile if it improves access to hospital systems, federal purchasing channels, or specialty distributors. The product’s practical licensing value depends on:
- Transferable FDA rights
- Manufacturing capacity
- Existing wholesale distribution
- Brand recognition
- Net pricing after rebates
- The ability to bundle the product with other cardiovascular assets
A buyer would likely value Inderal LA using a revenue multiple or discounted cash-flow approach based on stable cash generation, not on patent-adjusted peak sales. A high valuation would require evidence of durable supply advantages or a broader portfolio transaction.
No licensing transaction should be assumed in the base case without a disclosed agreement.
What revenue exposure does Inderal LA create for the manufacturer?
For a diversified pharmaceutical company, Inderal LA is unlikely to represent a material share of total revenue. The product’s risk is operational rather than transformational.
Revenue exposure is concentrated in:
- Manufacturing continuity
- Wholesale stocking
- Net price retention
- Generic competition
- Product liability and compliance
- Changes in reimbursement
A temporary plant issue could produce a disproportionate revenue decline because the product lacks strong pricing power. Conversely, a generic shortage could produce temporary upside, but sustained market share gains would require long-term supply and contracting advantages.
What are the likely generic launch scenarios?
Scenario 1: Stable generic competition
This is the most likely outcome. Existing ANDA holders maintain supply, generic prices remain low, and Inderal LA sales decline gradually.
Scenario 2: Generic consolidation
If one or more manufacturers exit, the remaining suppliers may gain volume and pricing power. Inderal LA could capture some prescriptions, but the effect would depend on whether payers permit brand reimbursement.
Scenario 3: Generic shortage
A short-term shortage could increase brand prescriptions and improve gross pricing. The benefit would likely last months rather than years.
Scenario 4: New branded lifecycle product
A manufacturer could pursue a modified-release formulation or new indication. This would require clinical, regulatory, and commercial investment and would face competition from low-cost propranolol products.
What is the geographic market outlook?
The United States is the most relevant market for Inderal LA because of its established branded product history and FDA-regulated generic market. Outside the United States, propranolol is widely available, but the specific Inderal LA brand may face different owners, labels, distributors, and generic competitors.
| Region | Outlook |
|---|---|
| United States | Mature branded and generic market |
| Europe | Generic-dominated; country-specific reimbursement |
| Canada | Mature market with generic substitution |
| Asia-Pacific | Larger volume potential, lower average prices |
| Latin America | Brand recognition may persist, but fragmented pricing |
| Emerging markets | Volume opportunity limited by low pricing |
International sales should not be projected from U.S. brand performance without country-level registration and distribution data.
Key Takeaways
- Inderal LA is an established extended-release propranolol product with no meaningful current patent-based exclusivity.
- The U.S. market is generic-dominated, and immediate-release propranolol is an important substitute.
- Estimated U.S. brand revenue is approximately $8 million to $12 million annually.
- Base-case sales are projected to remain near $9 million through 2030.
- Downside risk comes from formulary exclusion, generic price competition, and supply weakness.
- Upside depends mainly on generic shortages, improved contracting, or a new lifecycle strategy.
- Paragraph IV litigation and patent settlements are not central to the current commercial outlook.
- Inderal LA is a mature cash-flow asset, not a high-growth pharmaceutical product.
- The strongest residual advantages are clinical familiarity, patient continuity, and established distribution.
- The weakest factors are pricing power, payer preference, and patent protection.
FAQs
Does Inderal LA still have patent protection?
No material current patent barrier is expected to prevent generic competition. The original propranolol and extended-release protections have expired or no longer provide effective market exclusivity.
Is Inderal LA more profitable than generic propranolol?
Usually, the brand has a higher unit price, but generic propranolol has greater volume and stronger payer access. Profitability depends on manufacturing cost, rebate exposure, and the manufacturer’s distribution economics.
Can a new generic still launch for Inderal LA?
Yes. A manufacturer with an approved or newly approved ANDA can compete if it satisfies FDA quality and bioequivalence requirements and maintains commercial supply.
Is Inderal LA subject to biosimilar competition?
No. Propranolol is a small-molecule drug. Competition occurs through generic drug approvals rather than the biosimilar pathway.
What could materially increase Inderal LA sales?
The most credible short-term catalyst would be a sustained shortage among generic suppliers. A longer-term increase would require a new formulation, broader indication, improved reimbursement, or a distribution strategy that preserves brand prescriptions.
References
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
National Library of Medicine. (n.d.). DailyMed: Inderal LA propranolol hydrochloride extended-release capsule. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products and abbreviated new drug applications. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Generic drug facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
More… ↓
